IBM releases novel AI-powered technology to accelerate medical research for COVID-19
IBM has today released a new set of cloud- and AI-powered technologies to help researchers, doctors and scientists accelerate COVID-19 drug discovery.
These novel resources, from across IBM and available beginning today (Friday 3 April)...
Diagnostic devices reimagined
Diagnostic devices are coming on in leaps and bounds but you may be surprised to learn that one device that’s remained much the same since the late 1950s is the colonoscope. One researcher working...
Relentlessly searching for the cure
Martina Slapkova - Research Information Co-ordinator at the Motor Neurone Disease Association
Motor neuron disease (MND), also known as Amyotrophic Lateral Sclerosis across the globe, has been puzzling researchers and clinicians ever since it was...
Matching clinical trials with unmet clinical need
A new tool that helps target clinical trials to areas of unmet clinical need has sparked interest in both the National Health Service (NHS) and the commercial clinical research world. Stephen Lock, Head of...
Making clinical trials right for older people
In this issue, we speak to Miles Witham, Professor of Trials for Older People at Newcastle University and consultant geriatrician, about why he’s bringing about a sea change in how clinical trials involving older...
Bringing patients and providers together one tweet at a time
As an open forum for human interaction, social media have become the great equalizer of health information – providing a means for patients and health care providers to connect outside of the hospital or...
Adult Vaccination
“Vaccination can provide cost-effective protection against a host of diseases throughout life, but remains an underused public-health strategy in adults for the promotion of healthy ageing. Without specific vaccination programmes for the adult population...
Stay future-ready: Running parallel operations with a CDMO during clinical trials
Bringing a drug candidate through clinical trials is a challenging and high-risk process, since only 10% of candidates actually reach final approval. Both established pharma companies and small startups are often faced with this...